The mechanism and treatment strategies of SARS-CoV-2 mediated inflammatory response.
10.7507/1001-5515.202003030
- Author:
Ning HAN
1
;
Lingyao DU
1
;
Libo YAN
1
;
Hong TANG
1
Author Information
1. Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, P.R.China.
- Publication Type:Journal Article
- Keywords:
coronavirus disease 2019;
immunomodulatory therapy;
inflammatory response
- MeSH:
Betacoronavirus;
Coronavirus Infections;
Humans;
Pandemics;
Pneumonia, Viral
- From:Journal of Biomedical Engineering
2020;37(4):572-578
- CountryChina
- Language:Chinese
-
Abstract:
Since the emergence of novel coronavirus pneumonia in late 2019, it has quickly spread to many countries and regions around the world, causing a significant impact on human beings and society, posing a great threat to the global public health system. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was highly infectious, and some complications emerged rapidly in some patients, including acute respiratory distress syndrome, and multiple organ failure. The virus could trigger a series of immune responses, which might lead to excessive immune activation, thereby bringing about the immune system imbalance of the body. Up to now, there was no specific antiviral drug, and we conjectured that immunomodulatory therapy might play an essential part in the treatment of coronavirus disease 2019 (COVID-19) as adjuvant therapy. Therefore, we analyzed the possible mechanism of immune imbalance caused by the new coronavirus, and summarized the immunotherapeutic means of COVID-19 based on the mechanisms, to provide some reference for follow-up research and clinical prevention and treatment of COVID-19.
